Table 5.
Patient characteristics according to vaccine responsiveness in LC (univariate analysis)
| N | Good responders | Poor responders | p value |
|---|---|---|---|
| 9 | 13 | ||
| Recipient related factors | |||
| Age at OLT | 50 (47–55) | 54 (46–59) | 0.546 |
| Sex (male) | 8 (88 %) | 11 (84 %) | 0.774 |
| Time of vaccination (months after OLT) | 42 (26–50) | 30 (17–61) | 0.442 |
| HBsAg at OLT (≥1500 IU/l) | 6 (66 %) | 8 (61 %) | 0.805 |
| HBeAg positive at OLT | 6 (66 %) | 5 (38 %) | 0.190 |
| HBV DNA at OLT (≥3.7 logcopies/mL) | 4 (44 %) | 4 (30 %) | 0.513 |
| MELD at OLT | 15 [12–18] | 15 [8–19] | 0.480 |
| Child-Pugh score at OLT | 10 [8–10] | 9 [6–11] | 0.845 |
| HCC at OLT (+) | 6 (66 %) | 9 (69 %) | 0.899 |
| Anti-HBs antibody titer at the start of vaccination | 18.6 (6.4–34.6) | 17.4 (5.9–37.1) | 0.920 |
| Nucleos(t)ide analogue (LAM/LAM + ADV/ETV) | 6/3/0 | 8/3/2 | 0.312 |
| Tacrolimus/cyclosporinA | 6/3 | 11/1# | 0.148 |
| Tacrolimus level (ng/mL) | 4.7 (3.0–5.6) | 3.8 (2.9–5.8) | 0.744 |
| Donor-related factors | |||
| Age at OLT | 48 (47–51) | 33 (25–48) | 0.019* |
| Sex (M) | 2 (22 %) | 7 (53 %) | 0.138 |
| ABO (identical) | 3 (33 %) | 9 (69 %) | 0.093 |
| Blood relation (no) | 7 (77 %) | 1 (7 %) | <0.001* |
| Anti-HBs antibody titer (>100) | 6 (66 %) | 3 (23 %) | 0.038* |
| Anti-HBc antibody (+) | 6 (66 %) | 5 (38 %) | 0.190 |
| Anti-HBc(+)/anti-HBs(+) | 6 (66 %) | 4 (30 %) | 0.093 |
| Anti-HBc(+)/anti-HBs(−) | 0 (0 %) | 1 (7 %) | 0.297 |
| Anti-HBc(−)/anti-HBs(+) | 0 (0 %) | 0 (0 %) | – |
MELD Model for End-stage Liver Disease, HCC hepatocellular carcinoma, LAM lamivudine, ADV adefovir dipivoxyl, ETV entecavir
#One patient received no calcineurin inhibitor